RQM+ has acquired German CRO Kottmann in a move to expand the Pittsburgh-based medtech service’s offerings and global footprint.
Kottmann, which is based in Hamm, Germany, is focused on medical device clinical studies as well as in vitro diagnostics and pharmaceuticals. The company also offers development of databases (eCRFs), statistical evaluations and clinical monitoring.
“The German market, well known for its emphasis on science, innovation and market intelligence, is a vital geography for RQM+,” David Novotny, RQM+’s COO of clinical trial services, said in the release. “With the combined expertise of both organizations, we will achieve quicker, more efficient operational deliveries that will facilitate a faster market entry for our clients.”
Advising RQM+ in the acquisition were DLA Piper and Translink Corporate Finance. Financial terms of the deal weren’t disclosed in an August 28 press release.
Mergers and acquisitions in the CRO industry have been strong in the wake of the disruptions caused by the COVID-19 pandemic.
In the past few weeks alone, Sygnature Discovery acquired CRO NuChem Sciences, Frontage Labs picked up Nucro-Technics and Kohlberg & Co. bought Worldwide Clinical Trials.